Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.

STATUS

Recruiting
participants needed

11
sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Send

Updated on 19 February 2024

See if I qualify

cancer

platelet count

measurable disease

metastasis

neutrophil count

squamous cell carcinoma

skin cancer

cavity

carcinoma

head and neck carcinoma

squamous cell carcinoma of the head and neck

carcinoma in situ of the cervix

second malignancy

carcinoma in situ of cervix

io102

Summary

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.

Description

This proof of concept study will start with one control arm and one vaccine arm. The target of the first studied vaccine " IO102 " is the enzyme Indoleamine 2,3-dioxygenase (IDO). The vaccine is a amino acid peptide from indoleamine 2,3-dioxigenase. We are planning to add several other arms when other vaccines become clinically available.

The main objectives of this study are:

To evaluate the T-cell peptide-specific response to the vaccine in a interferon(INF)- ELISpot assay.
To assess the safety and tolerability of the vaccine.
To investigate the decreased action of the IDO enzyme in evaluating the increased tumoral infiltration by CD8+ T-lymphocytes and by measuring the serum levels of kynurenin, tryptophan,...
To evaluate the anti-tumor effect (objective response rate, overall survival, disease free- survival, disease specific survival).
To evaluate the pre-operative activity of peptide vaccine using MRI (Magnetic Resonance Imaging), DWI-MRI (Diffusion Weighted Imaging-MRI) and MRS (Magnetic Resonance Spectroscopy) to visualize possible significant tumor modifications.

Details

Condition	Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Age	18-100 years
Treatment	IO102
Clinical Study Identifier	NCT04445064
Sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Men and women 18 years of age on day of signing informed consent
	Histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx
	Patients selected for a surgical treatment
	No distant metastases
	Measurable disease as per RECIST 1.1
	No active second malignancy during the last 3 years except non melanomatous skin cancer or carcinoma in situ of the cervix
	The participant provides written signed informed consent for the trial in accordance with ICH-GCP and local legislation prior to admission to the trial
	Eastern Cooperative Oncology Group (ECOG) performance status scale 0-1 and Karnofsky score > or = 70
	Neutrophil count > 1,500/mm3, platelet count > 75,000/mm3, WBC> or = 3.0/109 L, bilirubin or creatinine < 2 times ULN, ALT or AST < 5 times ULN, Hemoglobin 9 g/dL
	A male participant able to father a child must agree to use contraception starting with the screening visit and throughout the duration of the trial
	A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies
	Not a woman of childbearing potential (WOCBP)
	A WOCBP who agrees to follow contraceptive guidance starting with the screening and throughout the duration of the trial. WOCBP are allowed in the trial if they are using proper contraception (follow guidelines from the European Union Heads of Medicines Agency (CTFG, 2014)
Exclusion Criteria
	Nasopharynx cancer, unknown primary and nasal cavity and paranasal sinuses carcinomas
	Previous exposure to immunotherapy
	Known diagnosis of immune deficiency or a positive serology of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
	Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) or pre-existing liver cirrhosis
	Other uncontrolled active illnesses or nonmalignant systemic disease (examples include, but are not limited to, active infections requiring antibiotics, bleeding disorders, uncontrolled diabetes, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome)
	Has received a live vaccine within 30 days prior to the first dose of trial treatment
	Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
	Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial treatment
	Any psychiatric, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
	Any malignancy (other than squamous cell carcinoma of the head and neck, non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer or basal cell carcinoma of the skin and carcinoma in situ of the cervix or bladder) within the last 3 years prior to registration
	Women of Child Bearing Potential (WOCBP) who has a positive urine pregnancy test (e.g., within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
	Pregnant woman and women who are expecting to conceive
	Breastfeeding women
	Patients expected to father children within the projected duration of the trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

squamous cell carcinoma

skin cancer

cavity

carcinoma

head and neck carcinoma

squamous cell carcinoma of the head and neck

carcinoma in situ of the cervix

second malignancy

carcinoma in situ of cervix

io102

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.